NCT01878019

Brief Summary

Background: \- Researchers want to look at how the brain responds to painful stimulations. They also want to see if these responses are different in people with and without chronic pain. To test the brain s response, they will use a chemical called naloxone. Naloxone is used to treat overdoses of painkilling drugs like morphine. It may be able to block the effect of a pain-relieving cream. Researchers will apply a pain-relieving cream to a person s lower leg and look at the results of sensitivity tests with either naloxone or a placebo. This study will compare the results from people with chronic pain (like fibromyalgia) to those of people without chronic pain. Objectives: \- To look at the brain s response to pain in people with and without chronic pain. Eligibility:

  • Individuals at least 18 years of age who have fibromyalgia.
  • Healthy volunteers at least 18 years of age. Design:
  • This study will involve a screening visit and two testing visits. The testing visits will be about a week apart.
  • Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. After the screening participants will be administered several questionnaires about their personality, and their thoughts and feelings.
  • At the first visit, participants will try out the magnetic resonance imaging (MRI) scan before using it at the next visit. They will then have the painkilling cream applied on one part of their lower leg and a normal moisturizing cream on the other part of their lower leg. They will have heat pulses on these skin areas and rate the pain.
  • At the second visit, participants will have tests in the MRI scanner. The heat pulse tests will be repeated after an infusion of either naloxone or a placebo.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
92

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started May 2013

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 28, 2013

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

June 12, 2013

Completed
2 days until next milestone

First Posted

Study publicly available on registry

June 14, 2013

Completed
3.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 8, 2016

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 8, 2016

Completed
Last Updated

December 9, 2019

Status Verified

September 8, 2016

Enrollment Period

3.3 years

First QC Date

June 12, 2013

Last Update Submit

December 6, 2019

Conditions

Keywords

PainPlaceboOpiate Antagonist

Outcome Measures

Primary Outcomes (1)

  • Pain Perception

    3 years

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient must be greater than or equal to 18 years of age.
  • Patient must be able to comprehend English.
  • Patient must be able to provide written informed consent.
  • Patient must have had chronic widespread pain for at least one year prior to participation with an average daily intensity at least 4 out of 10.
  • Healthy control must be greater than or equal to 18 years of age
  • Healthy control must be able to comprehend English.
  • Healthy control must be able to provide written informed consent.

You may not qualify if:

  • Patient is unable to comply with study procedures or follow-up visits
  • Patient smokes more than 10 cigarettes of nicotine per week.
  • Patient uses recreational drugs.
  • Female patient consumes more than 7 half-pint beers, 7 6-oz glasses of wine or 7 1-oz shots of spirits (or equivalent) per week, and male patient consumes 14 such drinks per week. Further, patient consumes more than 5 drinks at one time.
  • Patient is pregnant or breastfeeding.
  • Patient has a major medical condition, such as kidney, liver, cardiovascular, neurological or current psychiatric condition.
  • Patient has currently or has had in the past major depression, bipolar disorder, psychosis or suicide attempts.
  • Patient has metal in his/her body which would make having an MRI scan unsafe, such as pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent eye liner or small metal fragments in the eye that welders and other metal workers may have.
  • Patient is uncomfortable in small closed spaces (has claustrophobia) so that he/she would feel uncomfortable in the MRI machine.
  • Patient cannot lie comfortably flat on his/her back for up to 75 minutes in the MRI scanner.
  • Patient has allergies to topical treatment.
  • Patient has a chronic pain condition other than FM.
  • Patient has taken within the last two weeks opioids. Other medications used to treat fibromyalgia at the standard doses in the community can be taken. We will not ask participants to stop any medication to participate in the study.
  • Patient has previously taken opioids for more than one month on a continual basis, within the last 6 months.
  • Patient had seen study information on clinicaltrials.gov prior to September 23, 2013.
  • +9 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

National Institutes of Health Clinical Center, 9000 Rockville Pike

Bethesda, Maryland, 20892, United States

Location

Related Publications (3)

  • Apkarian AV, Sosa Y, Sonty S, Levy RM, Harden RN, Parrish TB, Gitelman DR. Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. J Neurosci. 2004 Nov 17;24(46):10410-5. doi: 10.1523/JNEUROSCI.2541-04.2004.

    PMID: 15548656BACKGROUND
  • Atlas LY, Bolger N, Lindquist MA, Wager TD. Brain mediators of predictive cue effects on perceived pain. J Neurosci. 2010 Sep 29;30(39):12964-77. doi: 10.1523/JNEUROSCI.0057-10.2010.

    PMID: 20881115BACKGROUND
  • Baliki MN, Geha PY, Fields HL, Apkarian AV. Predicting value of pain and analgesia: nucleus accumbens response to noxious stimuli changes in the presence of chronic pain. Neuron. 2010 Apr 15;66(1):149-60. doi: 10.1016/j.neuron.2010.03.002.

    PMID: 20399736BACKGROUND

MeSH Terms

Conditions

Pain

Condition Hierarchy (Ancestors)

Neurologic ManifestationsSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Mary C Bushnell, Ph.D.

    National Center for Complementary and Integrative Health (NCCIH)

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Time Perspective
PROSPECTIVE
Sponsor Type
NIH
Responsible Party
SPONSOR

Study Record Dates

First Submitted

June 12, 2013

First Posted

June 14, 2013

Study Start

May 28, 2013

Primary Completion

September 8, 2016

Study Completion

September 8, 2016

Last Updated

December 9, 2019

Record last verified: 2016-09-08

Locations